Ryuta Kinno
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ryuta Kinno has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
Mitsuru Kawamura
Division of Neurology, Department of Medicine, Showa Medical University , Shinagawa-ku, Tokyo 142-8666
10 shared publicationsTakashi Maruyama
Department of Neurosurgery, Tokyo Women's Medical University, Tokyo, Japan
9 shared publicationsTakahiro Yamazaki
Department of Internal Medicine, Showa University Northern Yokohama Hospital, Kanagawa, Japan
7 shared publicationsYoshihiro Muragaki
Department of Neurosurgery, Tokyo Women's Medical University, Tokyo, Japan; Department of Medical Device Engineering, Kobe University, Kobe, Japan
7 shared publications- Kenjiro Ono
Department of Neurology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan
6 shared publications Kuniyoshi L. Sakai
Department of Basic Science, Graduate School of Arts and Sciences, The University of Tokyo, Tokyo, Japan
6 shared publications
Latest Publications
- 2 July 2026
- Published by Wiley in Clinical and Experimental Neuroimmunology
- Vol. 17 (3)
Switching From Ravulizumab to Zilucoplan in Anti‐Acetylcholine Receptor Antibody–Positive Generalized Myasthenia Gravis: A Case Report
Background: Ravulizumab (RAV) is a long‐acting complement C5 inhibitor used to treat anti‐acetylcholine receptor (AChR)‐positive generalized myasthenia gravis (gMG). However, fluctuations in symptoms have been observed in some patients during RAV therapy. Here, we describe a patient with anti‐AChR antibody–positive gMG who developed recurrent worsening symptoms during the latter phase of the RAV dosing interval, and subsequently achieved symptom stabilization after switching to zilucoplan (ZIL). Case Presentation: A 58‐year‐old man with anti‐AChR antibody–positive gMG was treated with targeted immunotherapy and followed up longitudinally at our institution. He was diagnosed with gMG at 52 years of age and subsequently experienced repeated exacerbations and remissions. 6 years after disease onset, treatment with RAV was initiated, resulting in clinical improvement. However, after transitioning to the maintenance regimen, symptom recurrence consistently developed approximately 1 week before the next scheduled infusion. After switching to ZIL, these fluctuations resolved and his symptoms remained stable. Conclusions: The clinical course of this patient suggests an association between RAV treatment and the periodic worsening of symptoms. In this patient, the symptoms stabilized after switching to ZIL in combination with ongoing immunotherapy.
- 2 July 2026
- Published by Wiley in Clinical and Experimental Neuroimmunology
- Vol. 17 (3)
Switching From Ravulizumab to Zilucoplan in Anti‐Acetylcholine Receptor Antibody–Positive Generalized Myasthenia Gravis: A Case Report
Background: Ravulizumab (RAV) is a long‐acting complement C5 inhibitor used to treat anti‐acetylcholine receptor (AChR)‐positive generalized myasthenia gravis (gMG). However, fluctuations in symptoms have been observed in some patients during RAV therapy. Here, we describe a patient with anti‐AChR antibody–positive gMG who developed recurrent worsening symptoms during the latter phase of the RAV dosing interval, and subsequently achieved symptom stabilization after switching to zilucoplan (ZIL). Case Presentation: A 58‐year‐old man with anti‐AChR antibody–positive gMG was treated with targeted immunotherapy and followed up longitudinally at our institution. He was diagnosed with gMG at 52 years of age and subsequently experienced repeated exacerbations and remissions. 6 years after disease onset, treatment with RAV was initiated, resulting in clinical improvement. However, after transitioning to the maintenance regimen, symptom recurrence consistently developed approximately 1 week before the next scheduled infusion. After switching to ZIL, these fluctuations resolved and his symptoms remained stable. Conclusions: The clinical course of this patient suggests an association between RAV treatment and the periodic worsening of symptoms. In this patient, the symptoms stabilized after switching to ZIL in combination with ongoing immunotherapy.
- Open Access
- 22 May 2026
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 17, 304
Surgical treatment of apical petrositis through the anterior transpetrosal approach: A case report
Background: Apical petrositis is a rare but serious infection, often accompanied by osteomyelitis, that may cause cranial neuropathies and typically responds to antibiotics. However, surgical intervention may be required when medical therapy fails or when complications such as trigeminal neuralgia develop. Case Description: We report a rare case of apical petrositis that was successfully treated using the anterior transpetrosal approach. The patient was a 74-year-old woman who presented with pain in the distribution of the right mandibular division of the trigeminal nerve. A cystic lesion was identified in the right petrous apex, demonstrating low signal intensity on T1-weighted imaging and high signal intensity on T2-weighted imaging, with slight enhancement of the cyst wall, findings suggestive of apical petrositis. Antibiotic therapy was ineffective and her pain was not relieved with analgesics. Furthermore, imaging showed that the trigeminal nerve was displaced superiorly by bone expansion inside the petrous apex. Therefore, a right petrous apicectomy through an anterior transpetrosal approach was performed. During the operation, the dura mater was opened to examine the trigeminal nerve, which was surrounded by thickened and opaque arachnoid. The arachnoid was incised to decompress the nerve. Conclusion: This report highlights the importance of considering surgical intervention for apical petrositis, which may be necessary when antibiotic therapy fails.
- 22 May 2026
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 17, 304
Open AccessSurgical treatment of apical petrositis through the anterior transpetrosal approach: A case report
Background: Apical petrositis is a rare but serious infection, often accompanied by osteomyelitis, that may cause cranial neuropathies and typically responds to antibiotics. However, surgical intervention may be required when medical therapy fails or when complications such as trigeminal neuralgia develop. Case Description: We report a rare case of apical petrositis that was successfully treated using the anterior transpetrosal approach. The patient was a 74-year-old woman who presented with pain in the distribution of the right mandibular division of the trigeminal nerve. A cystic lesion was identified in the right petrous apex, demonstrating low signal intensity on T1-weighted imaging and high signal intensity on T2-weighted imaging, with slight enhancement of the cyst wall, findings suggestive of apical petrositis. Antibiotic therapy was ineffective and her pain was not relieved with analgesics. Furthermore, imaging showed that the trigeminal nerve was displaced superiorly by bone expansion inside the petrous apex. Therefore, a right petrous apicectomy through an anterior transpetrosal approach was performed. During the operation, the dura mater was opened to examine the trigeminal nerve, which was surrounded by thickened and opaque arachnoid. The arachnoid was incised to decompress the nerve. Conclusion: This report highlights the importance of considering surgical intervention for apical petrositis, which may be necessary when antibiotic therapy fails.
- Open Access
- 8 April 2026
- Published by Elsevier in Brain and Language
- Vol. 277, 105751
Sentence-level language processing speed in diffuse glioma: lesion location and contralesional structural variability
- 8 April 2026
- Published by Elsevier in Brain and Language
- Vol. 277, 105751
Open AccessSentence-level language processing speed in diffuse glioma: lesion location and contralesional structural variability
- Open Access
- 29 October 2025
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 7 (6)
The precuneus and posterior cingulate gyrus support temporal orientation in Alzheimer’s disease
Although the classifications of ‘past,’ ‘present,’ and ‘future’ are considered abstract concepts, we naturally understand them. Those classifications were named ‘A-series’ time by McTaggart in 1908. Alzheimer's disease (AD) is the most common type of dementia, with initial symptoms generally including temporal disorientation. This study aims to (1) elucidate the impairment process of temporal cognition in AD by administering A-series temporal tasks to individuals with AD, mild cognitive impairment (MCI), and healthy controls, and (2) clarify the relationship between temporal cognition at each stage of impairment and cerebral blood flow (CBF). A diagnosis of AD (n = 37), MCI (n = 10), and no dementia (ND) (n = 10) took part. The ‘A-series’ task consisted of eleven short sentences that were grammatically correct using seven-time qualifiers (last week, yesterday, today, now, tomorrow, this week, or next week). The participants were required to respond when the events in the sentences happened or would happen in nine stages. We compared the pattern of their responses, the scores of the Japanese version of the Mini-Mental State Examination (MMSE-J), and the regional CBFs performed by 99mTc-ethyl cysteinate dimer Single Photon Emission Computed Tomography. We found that ND was intact in the ability to distinguish between the past, present, and future, on the other hand, AD and MCI showed a diminished ability in temporal orientation when we sorted the 11 sentences in the ascending order of the mean response scores among the ND participants, they were generally ordered according to the time represented by adverbs of time. We also found that the participants could be best classified into three clusters. All ND participants (10/10) and half of the MCI participants (5/10) belonged to Cluster 1, whereas only 19% of the AD participants belonged to the cluster (7/37). Cluster 2 was contributed by three MCI participants (3/10) and 30% of the AD participants (11/37). Finally, most of the AD participants (51%) belonged to cluster 3 (19/37) with a few MCI participants (2/10). We compared CBFs across the three clusters and found the CBF in the pairs of the left and the right pericallosal region could predict whether a participant belonged to either cluster at the largest hit rate of 75%. Our findings suggest that the bilateral pericallosal region, including the posterior cingulate gyrus and precuneus cortex, is associated with temporal orientation.
- 29 October 2025
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 7 (6)
Open AccessThe precuneus and posterior cingulate gyrus support temporal orientation in Alzheimer’s disease
Although the classifications of ‘past,’ ‘present,’ and ‘future’ are considered abstract concepts, we naturally understand them. Those classifications were named ‘A-series’ time by McTaggart in 1908. Alzheimer's disease (AD) is the most common type of dementia, with initial symptoms generally including temporal disorientation. This study aims to (1) elucidate the impairment process of temporal cognition in AD by administering A-series temporal tasks to individuals with AD, mild cognitive impairment (MCI), and healthy controls, and (2) clarify the relationship between temporal cognition at each stage of impairment and cerebral blood flow (CBF). A diagnosis of AD (n = 37), MCI (n = 10), and no dementia (ND) (n = 10) took part. The ‘A-series’ task consisted of eleven short sentences that were grammatically correct using seven-time qualifiers (last week, yesterday, today, now, tomorrow, this week, or next week). The participants were required to respond when the events in the sentences happened or would happen in nine stages. We compared the pattern of their responses, the scores of the Japanese version of the Mini-Mental State Examination (MMSE-J), and the regional CBFs performed by 99mTc-ethyl cysteinate dimer Single Photon Emission Computed Tomography. We found that ND was intact in the ability to distinguish between the past, present, and future, on the other hand, AD and MCI showed a diminished ability in temporal orientation when we sorted the 11 sentences in the ascending order of the mean response scores among the ND participants, they were generally ordered according to the time represented by adverbs of time. We also found that the participants could be best classified into three clusters. All ND participants (10/10) and half of the MCI participants (5/10) belonged to Cluster 1, whereas only 19% of the AD participants belonged to the cluster (7/37). Cluster 2 was contributed by three MCI participants (3/10) and 30% of the AD participants (11/37). Finally, most of the AD participants (51%) belonged to cluster 3 (19/37) with a few MCI participants (2/10). We compared CBFs across the three clusters and found the CBF in the pairs of the left and the right pericallosal region could predict whether a participant belonged to either cluster at the largest hit rate of 75%. Our findings suggest that the bilateral pericallosal region, including the posterior cingulate gyrus and precuneus cortex, is associated with temporal orientation.
- Open Access
- 8 October 2025
- Published by MDPI AG in Neurology International
- Vol. 17 (10) , 163
Management of Myasthenic Crisis and Emerging Roles of Molecularly Targeted Therapies: A Narrative Review
Myasthenia gravis (MG) is a chronic autoimmune disorder characterized by fluctuating skeletal muscle weakness. Myasthenic crisis (MCr), a severe and potentially life-threatening complication, presents with respiratory failure and requires intensive care and rapid immunomodulatory intervention. Conventional MCr treatments—such as plasma exchange (PLEX), intravenous immunoglobulin (IVIG), and intravenous methylprednisolone (IVMP)—remain standard treatments; however, they present significant limitations, including delayed onset of action, adverse effects, and inconsistent efficacy. Recent therapeutic advances have led to the development of molecularly targeted therapies based on MG pathophysiology, particularly neonatal Fc receptor (FcRn) inhibitors and complement inhibitors, which have shown efficacy in refractory or maintenance settings. This review explores the potential application of these agents in MCr. We review published case reports involving FcRn inhibitors (efgartigimod, efgartigimod-SC, rozanolixizumab) and complement inhibitors (eculizumab, ravulizumab, zilucoplan), highlighting their rapid onset of action and safety profiles in MCr. While efgartigimod and eculizumab are the most commonly reported agents in MCr, data remain limited to small case series. Emerging evidence suggests these agents may offer effective alternatives to conventional therapies, with favorable safety and potential for rapid symptom resolution. We also discuss strategic considerations for therapy selection, including antibody subtype, coexisting autoimmune conditions, genetic factors, and transition to long-term maintenance. Though the current evidence is promising, large-scale randomized studies are needed to establish definitive roles for these therapies in MCr management.
- 8 October 2025
- Published by MDPI AG in Neurology International
- Vol. 17 (10) , 163
Open AccessManagement of Myasthenic Crisis and Emerging Roles of Molecularly Targeted Therapies: A Narrative Review
Myasthenia gravis (MG) is a chronic autoimmune disorder characterized by fluctuating skeletal muscle weakness. Myasthenic crisis (MCr), a severe and potentially life-threatening complication, presents with respiratory failure and requires intensive care and rapid immunomodulatory intervention. Conventional MCr treatments—such as plasma exchange (PLEX), intravenous immunoglobulin (IVIG), and intravenous methylprednisolone (IVMP)—remain standard treatments; however, they present significant limitations, including delayed onset of action, adverse effects, and inconsistent efficacy. Recent therapeutic advances have led to the development of molecularly targeted therapies based on MG pathophysiology, particularly neonatal Fc receptor (FcRn) inhibitors and complement inhibitors, which have shown efficacy in refractory or maintenance settings. This review explores the potential application of these agents in MCr. We review published case reports involving FcRn inhibitors (efgartigimod, efgartigimod-SC, rozanolixizumab) and complement inhibitors (eculizumab, ravulizumab, zilucoplan), highlighting their rapid onset of action and safety profiles in MCr. While efgartigimod and eculizumab are the most commonly reported agents in MCr, data remain limited to small case series. Emerging evidence suggests these agents may offer effective alternatives to conventional therapies, with favorable safety and potential for rapid symptom resolution. We also discuss strategic considerations for therapy selection, including antibody subtype, coexisting autoimmune conditions, genetic factors, and transition to long-term maintenance. Though the current evidence is promising, large-scale randomized studies are needed to establish definitive roles for these therapies in MCr management.
- 23 July 2025
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 257, 109063
Recurrent stroke due to biatrial myxoma lacking typical transesophageal echocardiographic findings
- 23 July 2025
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 257, 109063
Recurrent stroke due to biatrial myxoma lacking typical transesophageal echocardiographic findings
- Open Access
- 10 June 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1605985
Case Report: Therapeutic effect of efgartigimod in refractory anti-GQ1b antibody syndrome coexisting with myasthenia gravis
Anti-GQ1b antibody syndrome is a spectrum of autoimmune neurological disorders that includes Miller Fisher syndrome, Guillain-Barré syndrome (GBS) with ophthalmoplegia, Bickerstaff brainstem encephalitis, and acute ophthalmoplegia without ataxia. These conditions are characterized by the presence of immunoglobulin G (IgG) antibodies targeting GQ1b gangliosides. The coexistence of anti-GQ1b antibody syndrome and myasthenia gravis (MG) is rare and presents diagnostic and therapeutic challenges. We report the case of an 84-year-old Japanese man with overlapping features of both disorders, describing his clinical course and response to add-on treatment with the neonatal Fc receptor antagonist efgartigimod. He presented with fever and diarrhea, followed by acute limb weakness. He was initially suspected of having had a stroke but was later diagnosed with GBS based on areflexia, anti-ganglioside antibody positivity, and nerve conduction abnormalities. Intravenous immunoglobulin therapy was initiated but his condition worsened, leading to respiratory failure and mechanical ventilation. Subsequently, bilateral ptosis and eye movement dysfunction emerged, prompting the consideration of MG. Anti-acetylcholine receptor antibodies and tensilon test results were positive and high-dose methylprednisolone was administered, resulting in partial improvement. Plasmapheresis was performed, but profound limb weakness and respiratory failure persisted; intravenous efgartigimod was thus introduced. Remarkably, the patient’s respiratory function improved within 7 days, leading to ventilator weaning, and his limb weakness showed notable recovery. After a second cycle of efgartigimod, the patient regained speech and independent mobility, allowing transfer to a rehabilitation facility. His case underscores the diagnostic complexity of overlapping anti-GQ1b antibody syndrome and MG, and it highlights the therapeutic potential of efgartigimod in treating refractory cases of overlapping autoimmune neuromuscular syndromes. Given the rapid efficacy of efgartigimod for improving both respiratory and motor functions in this case, it is apparent that efgartigimod can be a valuable therapeutic option in complex neuromuscular autoimmune conditions.
- 10 June 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1605985
Open AccessCase Report: Therapeutic effect of efgartigimod in refractory anti-GQ1b antibody syndrome coexisting with myasthenia gravis
Anti-GQ1b antibody syndrome is a spectrum of autoimmune neurological disorders that includes Miller Fisher syndrome, Guillain-Barré syndrome (GBS) with ophthalmoplegia, Bickerstaff brainstem encephalitis, and acute ophthalmoplegia without ataxia. These conditions are characterized by the presence of immunoglobulin G (IgG) antibodies targeting GQ1b gangliosides. The coexistence of anti-GQ1b antibody syndrome and myasthenia gravis (MG) is rare and presents diagnostic and therapeutic challenges. We report the case of an 84-year-old Japanese man with overlapping features of both disorders, describing his clinical course and response to add-on treatment with the neonatal Fc receptor antagonist efgartigimod. He presented with fever and diarrhea, followed by acute limb weakness. He was initially suspected of having had a stroke but was later diagnosed with GBS based on areflexia, anti-ganglioside antibody positivity, and nerve conduction abnormalities. Intravenous immunoglobulin therapy was initiated but his condition worsened, leading to respiratory failure and mechanical ventilation. Subsequently, bilateral ptosis and eye movement dysfunction emerged, prompting the consideration of MG. Anti-acetylcholine receptor antibodies and tensilon test results were positive and high-dose methylprednisolone was administered, resulting in partial improvement. Plasmapheresis was performed, but profound limb weakness and respiratory failure persisted; intravenous efgartigimod was thus introduced. Remarkably, the patient’s respiratory function improved within 7 days, leading to ventilator weaning, and his limb weakness showed notable recovery. After a second cycle of efgartigimod, the patient regained speech and independent mobility, allowing transfer to a rehabilitation facility. His case underscores the diagnostic complexity of overlapping anti-GQ1b antibody syndrome and MG, and it highlights the therapeutic potential of efgartigimod in treating refractory cases of overlapping autoimmune neuromuscular syndromes. Given the rapid efficacy of efgartigimod for improving both respiratory and motor functions in this case, it is apparent that efgartigimod can be a valuable therapeutic option in complex neuromuscular autoimmune conditions.
- Open Access
- 13 December 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (50) , e40912
Successful management of immunotherapy-resistant respiratory failure in anti-mitochondrial M2 antibody-positive myositis by modified lung volume recruitment therapy: A case report
Rationale: Anti-mitochondrial antibodies (AMA) M2-positive myositis can lead to severe respiratory failure. Traditional immunotherapies sometimes fail to address respiratory failure. Herein, this CARE-compliant case report described a patient with AMA-M2-positive myositis who recovered from ventilation with tracheostomy owing to immunotherapy-resistant respiratory failure to spontaneous breathing after modified lung volume recruitment (mLVR) therapy. Patient concerns: A 60-year-old man experienced general fatigue and shortness of breath. The patient had a notable degree of proximal muscle weakness. Blood test results revealed hyperCKemia. The serum AMA-M2 antibody was positive. A muscle magnetic resonance imaging revealed diffuse abnormal hyperintensities in both lower limb muscles. Needle electromyography demonstrated fibrillation and positive sharp waves at rest with early recruitment, suggesting myogenic changes. Progressive muscle weakness and clinical findings fulfilled the criteria for definite idiopathic inflammatory myopathy. We diagnosed him with AMA-M2-positive myositis. Notably, his thoracic mobility was decreased, resulting in CO2 narcosis, requiring ventilation. Two courses of intravenous methylprednisolone for 3 days followed by oral prednisolone for myopathy. However, his respiratory function remained compromised, resulting in a tracheostomy. Diagnoses: We diagnosed him with severe immunotherapy-resistant respiratory failure due to AMA-positive myositis that required ventilation and tracheostomy. Interventions: To address respiratory failure, this patient underwent the mLVR therapy using the LIC TRAINER (LT). The pressure was adjusted by the operator using a bag-valve mask (BVM), starting at 1500 mL and increasing it up to a maximum of 2500 mL, while avoiding excessive airway pressure. Outcomes: Respiratory function was evaluated by objective measures using chest wall mobility, inspiratory capacity (IC), vital capacity (VC), tidal volume (TV), and subjective measures using the visual analogue scale (VAS). Both objective and subjective scales showed significant improvements. The patient was weaned off ventilation 48 days after the initiation of mLVR therapy. Lessons: The mLVR therapy is an effective respiratory rehabilitation for patients with weakened respiratory muscles or tracheostomy. It allows the intensity of treatment to be adjusted based on the patient’s symptoms, making it both highly effective and safe. This case suggests that mLVR therapy may be effective in treating severe, immunotherapy-resistant respiratory failure in AMA-positive myositis.
- 13 December 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (50) , e40912
Open AccessSuccessful management of immunotherapy-resistant respiratory failure in anti-mitochondrial M2 antibody-positive myositis by modified lung volume recruitment therapy: A case report
Rationale: Anti-mitochondrial antibodies (AMA) M2-positive myositis can lead to severe respiratory failure. Traditional immunotherapies sometimes fail to address respiratory failure. Herein, this CARE-compliant case report described a patient with AMA-M2-positive myositis who recovered from ventilation with tracheostomy owing to immunotherapy-resistant respiratory failure to spontaneous breathing after modified lung volume recruitment (mLVR) therapy. Patient concerns: A 60-year-old man experienced general fatigue and shortness of breath. The patient had a notable degree of proximal muscle weakness. Blood test results revealed hyperCKemia. The serum AMA-M2 antibody was positive. A muscle magnetic resonance imaging revealed diffuse abnormal hyperintensities in both lower limb muscles. Needle electromyography demonstrated fibrillation and positive sharp waves at rest with early recruitment, suggesting myogenic changes. Progressive muscle weakness and clinical findings fulfilled the criteria for definite idiopathic inflammatory myopathy. We diagnosed him with AMA-M2-positive myositis. Notably, his thoracic mobility was decreased, resulting in CO2 narcosis, requiring ventilation. Two courses of intravenous methylprednisolone for 3 days followed by oral prednisolone for myopathy. However, his respiratory function remained compromised, resulting in a tracheostomy. Diagnoses: We diagnosed him with severe immunotherapy-resistant respiratory failure due to AMA-positive myositis that required ventilation and tracheostomy. Interventions: To address respiratory failure, this patient underwent the mLVR therapy using the LIC TRAINER (LT). The pressure was adjusted by the operator using a bag-valve mask (BVM), starting at 1500 mL and increasing it up to a maximum of 2500 mL, while avoiding excessive airway pressure. Outcomes: Respiratory function was evaluated by objective measures using chest wall mobility, inspiratory capacity (IC), vital capacity (VC), tidal volume (TV), and subjective measures using the visual analogue scale (VAS). Both objective and subjective scales showed significant improvements. The patient was weaned off ventilation 48 days after the initiation of mLVR therapy. Lessons: The mLVR therapy is an effective respiratory rehabilitation for patients with weakened respiratory muscles or tracheostomy. It allows the intensity of treatment to be adjusted based on the patient’s symptoms, making it both highly effective and safe. This case suggests that mLVR therapy may be effective in treating severe, immunotherapy-resistant respiratory failure in AMA-positive myositis.
- Open Access
- 22 January 2024
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 15, 1321058
Case report: Recovery from refractory myasthenic crisis to minimal symptom expression after add-on treatment with efgartigimod
Myasthenic crisis, a life-threatening exacerbation of myasthenia gravis, is a significant clinical challenge, particularly when refractory to standard therapies. Here, we described a case of myasthenic crisis in which the patient transitioned from refractory myasthenic crisis to minimal symptom expression after receiving add-on treatment with efgartigimod, a novel neonatal Fc receptor antagonist. A 54 years-old woman who was diagnosed with anti-acetylcholine receptor antibody-positive myasthenia gravis experienced respiratory failure necessitating mechanical ventilation. Despite aggressive treatment with plasmapheresis, intravenous immunoglobulins, and high-dose corticosteroids, her condition continued to deteriorate, culminating in persistent myasthenic crisis. Efgartigimod was administered as salvage therapy. Remarkable improvement in neuromuscular function was observed within days, allowing for successful weaning from mechanical ventilation. Over the subsequent weeks, the patient’s symptoms continued to ameliorate, ultimately reaching a state of minimal symptom expression. Serial assessments of her serum anti-acetylcholine receptor antibody titer showed a consistent decline in parallel with this clinical improvement. This case highlights efgartigimod’s potential as an effective therapeutic option for refractory myasthenic crisis, offering new hope for patients facing this life-threatening condition.
- 22 January 2024
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 15, 1321058
Open AccessCase report: Recovery from refractory myasthenic crisis to minimal symptom expression after add-on treatment with efgartigimod
Myasthenic crisis, a life-threatening exacerbation of myasthenia gravis, is a significant clinical challenge, particularly when refractory to standard therapies. Here, we described a case of myasthenic crisis in which the patient transitioned from refractory myasthenic crisis to minimal symptom expression after receiving add-on treatment with efgartigimod, a novel neonatal Fc receptor antagonist. A 54 years-old woman who was diagnosed with anti-acetylcholine receptor antibody-positive myasthenia gravis experienced respiratory failure necessitating mechanical ventilation. Despite aggressive treatment with plasmapheresis, intravenous immunoglobulins, and high-dose corticosteroids, her condition continued to deteriorate, culminating in persistent myasthenic crisis. Efgartigimod was administered as salvage therapy. Remarkable improvement in neuromuscular function was observed within days, allowing for successful weaning from mechanical ventilation. Over the subsequent weeks, the patient’s symptoms continued to ameliorate, ultimately reaching a state of minimal symptom expression. Serial assessments of her serum anti-acetylcholine receptor antibody titer showed a consistent decline in parallel with this clinical improvement. This case highlights efgartigimod’s potential as an effective therapeutic option for refractory myasthenic crisis, offering new hope for patients facing this life-threatening condition.
- Open Access
- 6 November 2023
- Published by Springer Nature in Journal of NeuroVirology
- Vol. 29 (6) , 731-733
Acute cerebellitis following COVID-19 infection associated with autoantibodies to glutamate receptors: a case report
While COVID-19 infection by the SARS-CoV-2 virus was initially identified as a respiratory disease, mounting evidence suggests its association with various neurological issues as well. Notably, COVID-19 has been linked to acute cerebellitis (AC) and post-infectious cerebellar ataxia. The precise underlying mechanisms behind these neurological effects remain unclear. Our case report describes AC following COVID-19 infection, associated with autoantibodies to glutamate receptors (GluRs), hinting at immunological involvement. The case is a 56-year-old woman who experienced fever and fatigue due to COVID-19 infection. About 2 weeks after these symptoms improved, she showed cerebellar symptoms such as ocular overshoot and ataxia when presenting to our hospital. Her cerebrospinal fluid (CSF) findings were normal. Brain MRI revealed cerebellar abnormalities. Treatment with methylprednisolone led to symptom improvement. Later tests of CSF yielded positive results for autoantibodies to GluRs. Our findings suggest a possible immune-mediated mechanism in the onset of AC following COVID-19 infection. Clinicians should consider the possibility of immunological pathogenesis when diagnosing cerebellar symptoms after COVID-19 infection.
- 6 November 2023
- Published by Springer Nature in Journal of NeuroVirology
- Vol. 29 (6) , 731-733
Open AccessAcute cerebellitis following COVID-19 infection associated with autoantibodies to glutamate receptors: a case report
While COVID-19 infection by the SARS-CoV-2 virus was initially identified as a respiratory disease, mounting evidence suggests its association with various neurological issues as well. Notably, COVID-19 has been linked to acute cerebellitis (AC) and post-infectious cerebellar ataxia. The precise underlying mechanisms behind these neurological effects remain unclear. Our case report describes AC following COVID-19 infection, associated with autoantibodies to glutamate receptors (GluRs), hinting at immunological involvement. The case is a 56-year-old woman who experienced fever and fatigue due to COVID-19 infection. About 2 weeks after these symptoms improved, she showed cerebellar symptoms such as ocular overshoot and ataxia when presenting to our hospital. Her cerebrospinal fluid (CSF) findings were normal. Brain MRI revealed cerebellar abnormalities. Treatment with methylprednisolone led to symptom improvement. Later tests of CSF yielded positive results for autoantibodies to GluRs. Our findings suggest a possible immune-mediated mechanism in the onset of AC following COVID-19 infection. Clinicians should consider the possibility of immunological pathogenesis when diagnosing cerebellar symptoms after COVID-19 infection.